13F Holdings
中文EN

OPHI CollPlant Biotechnologies Ltd

Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1631487 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY360.4%
TTM net income YoY30.8%
TTM EPS YoY35.2%
Revenue 3-yr CAGR99.4%
Net income 3-yr CAGR—

Margins

Gross margin64.8%
Operating margin-484.3%
Net margin-484.6%
FCF margin-398.4%
EBITDA margin-445.8%

Returns

ROE-117.6%
ROA-77.9%
ROIC (approx.)-886.8%
Asset turnover0.16x

Leverage & solvency

Liabilities / assets43.6%
Debt / equity0.00x
Current ratio2.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.37M$515,000$10.96M$299,000$15.64M
Cost of revenue$835,000$1.62M$1.99M$400,000$2.00M
Gross profit$1.54M-$1.11M$8.97M-$101,000$13.64M
R&D expense$8.19M$10.52M$10.48M$10.26M$7.63M
SG&A expense$4.83M$5.63M$6.00M$6.74M$5.94M
Operating income-$11.48M-$17.25M-$7.51M-$17.10M$65,000
Income tax—$45.99M$59.99M——
Net income-$11.49M-$16.61M-$7.02M-$16.93M$237,000
EBITDA-$10.57M-$16.21M-$6.41M-$16.02M$838,000
EPS (basic)-0.94-1.45-0.62-1.530.02
EPS (diluted)-0.94-1.45-0.62-1.530.02
Weighted avg. shares (diluted)12.20M11.45M11.39M11.03M11.97M
Balance sheet
Cash & equivalents$5.59M$11.91M$26.67M$29.86M$13.37M
Receivables$1,000$150,000—$9,000$270,000
Inventory$573,000$440,000$714,000$1.43M$1.08M
Current assets$6.75M$13.18M$28.02M$31.66M$45.09M
PP&E, net$1.46M$2.29M$2.79M$2.97M$2.73M
Intangibles$73,000$131,000$188,000$245,000$243,000
Total assets$10.79M$18.71M$34.13M$37.77M$51.22M
Current liabilities$2.67M$2.97M$3.25M$3.10M$3.01M
Short-term debt———$321,000$219,000
Long-term debt————$30,000
Total debt————$249,000
Total liabilities$4.70M$5.25M$5.79M$5.49M$6.10M
Shareholders' equity$6.08M$13.46M$28.34M$32.28M$45.12M
Net debt————-$13.12M
Shares outstanding12.80M11.45M11.45M11.19M10.77M
Cash flow statement
Operating cash flow-$9.42M-$14.09M-$2.76M-$13.70M$2.50M
Capital expenditure$28,000$483,000$954,000$1.27M$1.43M
Free cash flow-$9.45M-$14.58M-$3.72M-$14.97M$1.07M
Investing cash flow-$27,000-$539,000-$1.16M$28.92M-$31.56M
Financing cash flow$3.10M$9,000$1.11M$1.87M$38.76M
Depreciation & amortization$912,000$1.04M$1.10M$1.08M$773,000
Stock-based compensation$999,000$1.72M$1.94M$2.17M$1.60M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.